Glenmark Pharmaceuticals and Helsinn Group (Helsinn), a Swiss pharmaceutical group focused on building quality cancer care products, have entered into an exclusive licensing agreement to introduce AKYNZEO in India and Nepal.
AKYNZEO, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of chemotherapy-induced nausea and vomiting (CINV). The licensing agreement with Glenmark for AKYNZEO represents Helsinn's first such agreement in India. Glenmark will have exclusive marketing rights for AKYNZEO in India and Nepal.
Glenmark has received marketing approval for AKYNZEO from the Central Drugs Standard Control Organization (CDSCO).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
